OPEN TO ACCCRUALS
Study / IRB number / Clinicaltrial.gov
- A Phase II Study to Test the Efficacy of AB928 (Dual Adenosine Receptor Antagonist) and AB122 (a PD1 Checkpoint Inhibitor) in Combination With Short Course Radiotherapy and Consolidation Chemotherapy for Rectal Cancer (PANTHER) 21-02023289 NCT05024097
- Randomized Phase II Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate Cancer (FORT) 21-02023315 NCT04984343
- De-convoluting interactions between genes, the cancer environment, and the immune system to develop therapies that work for you (DIGNITY) 21-06023682 NCT05134779
- Pembrolizumab and Stereotactic Radiosurgery (SRS) Of Selected Brain Metastases In Breast Cancer Patients 1710018694 NCT03449238
- Prospective Randomized study of Accelerated Radiation Therapy (PRART) 19-07020533 NCT04175210
- Converting HR+ Breast Cancer Into an Individualized Vaccine (CBCV) 19-07020531 NCT03804944
- Personalized Second Chance Breast Conservation (PSCBC): A Two Center Prospective Phase II Clinical Study 19-07020531 NCT04371913
- Single-Arm Phase II Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer (PSMA SBRT-SIB) 19-10020928 NCT04402151
- Combined Immunotherapies in Metastatic ER+ Breast Cancer (CIMER) 19-04020263 NCT04220476
- Pilot/feasibility study of pulmonary nodules and coronary calcification screening at standard Computed Tomography simulation for breast cancer radiotherapy (Screening from CT Simulation, SCTS) 23-08026342 NOT AVAILABLE
- The Radiation Oncology-Biology Integration Network (ROBIN) Molecular Characterization Trial (MCT) of Standard Short Course Radiotherapy for Rectal Cancer (ROBIN) 22-08025121 NCT05943210
NOT ACCEPTING ANY NEW PATIENTS (CLOSED TO ENROLLMENT)
- A Multi-Center study of Androgen Suppression with abiraterone aCetate, LEuprolide, PARP Inhibition and Stereotactic body radiotherapy (ASCLEPIuS): A phase I/2 trial in high risk or node positive prostate cancer - (SPONSOR - University of Michigan) 20-10022843 NCT04194554
- Randomized Phase II Trial of Salvage Radiotherapy for Prostate Cancer In 4 Weeks v. 2 Weeks (SHORTER) 20-03021572 NCT04422132
- NYP- WELCOME trial (Weill Cornell Medicine Employees) 20-04021831 NOT AVAILABLE
- Prone partial breast irradiation (PBI): Prospective randomized controlled non-inferiority trial to compare radiation fibrosis with five versus three fractions 1505016201 NCT02755896
- Accelerated Radiation Therapy (ART) To the Breast and Nodal Stations after Neo-Adjuvant Chemotherapy and Surgery: A Feasibility Study 1602017017 NCT02917421
- PRE-ProstAtectomy MRI-GuidEd Stereotactic Body RadioTherapy (PREPARE) for High-Risk Prostate Cancer Trial 1712018849 NCT03663218
- Prostate Radio Ablation Guided by Magnetic Resonance Imaging Acquisition (PRAGMA) in Metastatic Prostate Cancer 19-04020263 NCT04220983
- Prospective phase II Study of Stereotactic MR-guided on-table Adaptive Radiation Therapy (SMART) for Patients with Borderline or Inoperable Locally Advanced Pancreatic Cancer 19-04020160 NCT03621644
- Effect of radiotherapy variables on circulating effectors of immune response and local microbiome 1708018471 NCT03383107
- RTOG0534: A Phase III Trial of Short-Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only RT (SPORT) in Prostate Cancer Patients with a Rising PSA after Radical Prostatectomy 0810010069 NCT00567580
- NRG GU003 - A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT) 1708018460 NCT03274687
- Radiation and immune checkpoints blockade in metastatic NSCLC 1607017434 NCT03168464
CLOSED STUDIES
- An Open-Label Multicenter Phase 1b Study of E7046 in Combination with Radiotherapy/ Chemo radiotherapy (RT/CRT) in preoperative treatment of Subjects with Rectum Cancer 1612017834 NCT03152370
- A Phase II randomized controlled trial of PD-1/PDL-1 axis blockade versus PD-1/PDL-1 axis blockade plus radiotherapy in metastatic genitourinary (renal/urothelial) malignancies 1606017369 NCT03115801
- MRI-guided Stereotactic Body Radiotherapy (SBRT) With Simultaneous Integrated Boost for Prostate Cancer (SIBRT) 1802019010 NCT03664193
- ISABR STUDY: A Multi-Site Randomized Phase I/II Study of Stereotactic Ablative Body Radiotherapy +/- MEDI 4736 (Durvalumab) for Medically Inoperable Early- Stage Non-Small Cell Lung Cancer 19-04020249 NCT03148327
- Randomized trial of image-guided stereotactic radiation therapy (IG-SRT) in prostate cancer 1604017139 NCT02911922
- A First-in-Human Study of Repeat Dosing with REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination with Other Anti-Cancer Therapies in Patients with Advanced Malignancies 1505016229 NCT02383212
- LY2157299 Monohydrate (LY2157299) and Radiotherapy in Metastatic Breast Cancer 1505016222 NCT02538471
- Phase I/II study of TLR7 agonist Imiquimod, Cyclophosphamide, and Radiotherapy in Breast Cancer Patients with Chest Wall Recurrence or Skin Metastases 1505016228 NCT01421017